3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Melanoma
56
Carcinoma, Non-Small-Cell Lung
56
Carcinoma, Renal Cell
34
Neoplasms
33
Neoplasm Metastasis
29
Colorectal Neoplasms
23
Squamous Cell Carcinoma of Head and Neck
22
Pancreatic Neoplasms
22
Carcinoma, Hepatocellular
21
Carcinoma, Transitional Cell
18
Lung Neoplasms
17
Glioblastoma
15
Ovarian Neoplasms
14
Triple Negative Breast Neoplasms
13
Breast Neoplasms
13
Urinary Bladder Neoplasms
11
Stomach Neoplasms
11
Head and Neck Neoplasms
10
Uveal Melanoma
9
Recurrence
8
Myelodysplastic Syndromes
8
Lymphoma
8
Leukemia, Myeloid, Acute
8
Advanced Cancer
8
Small Cell Lung Carcinoma
7
Multiple Myeloma
7
Kidney Neoplasms
7
Hodgkin Disease
7
Hematologic Neoplasms
7
Glioma
7
Interventions
dacetuzumab
4
tetulomab tetraxetan lu-177
2
Rituximab
2
Lutetium
2
Gemcitabine
2
vandetanib
1
tirbanibulin
1
phenethyl isothiocyanate
1
motesanib diphosphate
1
imetelstat
1
fludarabine
1
ficlatuzumab
1
denileukin diftitox
1
beta-Glucans
1
Nivolumab
1
Lutetium-177
1
Lenalidomide
1
Immunoenzyme Techniques
1
Ganciclovir
1
Erlotinib Hydrochloride
1
Dexamethasone
1
Clofarabine
1
Calcium Dobesilate
1
Bortezomib
1
Bevacizumab
1
Bendamustine Hydrochloride
1
AP 1903 reagent
1
4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Lymphoproliferative Disorders
×
Nivolumab
×
Clear all
NCT02973113
2021-07-21
PREVALE
Baylor College of Medicine
Phase 1
Completed
8 enrolled